{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T07:42:48Z","timestamp":1762674168113,"version":"3.41.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,3,14]],"date-time":"2017-03-14T00:00:00Z","timestamp":1489449600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Bone Miner Metab"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1007\/s00774-017-0829-4","type":"journal-article","created":{"date-parts":[[2017,3,14]],"date-time":"2017-03-14T11:54:51Z","timestamp":1489492491000},"page":"221-228","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Effect of osteoporosis medication on changes in bone mineral density and bone turnover markers after 24-month administration of daily teriparatide: comparison among minodronate, raloxifene, and eldecalcitol"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7928-0014","authenticated-orcid":false,"given":"Shinichi","family":"Nakatoh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,3,14]]},"reference":[{"key":"829_CR1","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s00774-013-0546-6","volume":"32","author":"T Yamamoto","year":"2014","unstructured":"Yamamoto T, Taketsuna M, Guo X, Sato M, Sowa H (2014) The safety and effectiveness profile of daily teriparatide in a prospective observational study in Japanese patients with osteoporosis at high risk for fracture: interim report. J Bone Miner Metab 32:699\u2013708","journal-title":"J Bone Miner Metab"},{"key":"829_CR2","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1359\/JBMR.050501","volume":"20","author":"R Prince","year":"2005","unstructured":"Prince R, Sipos A, Hossain A, Syversen U, Ish-Shalom S, Marcinowska E, Halse J, Lindsay R, Dalsky GP, Mitlak BH (2005) Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment. J Bone Miner Res 20:1507\u20131513","journal-title":"J Bone Miner Res"},{"key":"829_CR3","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1530\/EJE-11-0740","volume":"166","author":"F Jakob","year":"2012","unstructured":"Jakob F, Oertel H, Langdahl B, Ljunggren O, Barrett A, Karras D, Walsh JB, Fahrleitner-Pammer A, Rajzbaum G, Barker C, Lems WF, Marin F (2012) Effects of teriparatide in postmenopausal women with osteoporosis pre-treated with bisphosphonates: 36-month results from the European Forsteo Observational Study. Eur J Endocrinol 166:87\u201397","journal-title":"Eur J Endocrinol"},{"key":"829_CR4","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1359\/jbmr.081215","volume":"24","author":"R Eastell","year":"2009","unstructured":"Eastell R, Nickelsen T, Marin F, Barker C, Hadji P, Farrerons J, Audran M, Boonen S, Brixen K, Gomes JM, Obermayer-Pietsch B, Avramidis A, Sigurdsson G, Gl\u00fcer CC (2009) Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS). J Bone Miner Res 24:726\u2013736","journal-title":"J Bone Miner Res"},{"key":"829_CR5","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1210\/jc.2008-2630","volume":"94","author":"BZ Leder","year":"2009","unstructured":"Leder BZ, Neer RM, Wyland JJ, Lee HW, Burnett-Bowie SM, Finkelstein JS (2009) Effects of teriparatide treatment and discontinuation in postmenopausal women and eugonadal men with osteoporosis. J Clin Endocrinol Metab 94:2915\u20132921","journal-title":"J Clin Endocrinol Metab"},{"key":"829_CR6","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s00198-007-0485-y","volume":"19","author":"S Adami","year":"2008","unstructured":"Adami S, San Martin J, Mu\u00f1oz-Torres M, Econs MJ, Xie L, Dalsky GP, McClung M, Felsenberg D, Brown JP, Brandi ML, Sipos A (2008) Effect of raloxifene after recombinant teriparatide [hPTH(1-34)] treatment in postmenopausal women with osteoporosis. Randomized controlled trial. Osteoporos Int 19:87\u201394","journal-title":"Osteoporos Int"},{"key":"829_CR7","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1001\/jama.285.6.785","volume":"285","author":"NIH consensus Development Panel on Osteoporosis Prevention","year":"2001","unstructured":"NIH consensus Development Panel on Osteoporosis Prevention (2001) Diagnosis, and therapy. JAMA 285:785\u2013795","journal-title":"JAMA"},{"key":"829_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00774-012-0392-y","volume":"31","author":"Y Nishizawa","year":"2013","unstructured":"Nishizawa Y, Ohta H, Miura M, Inaba M, Ichimura S, Shiraki M, Takada J, Chaki O, Hagino H, Fujiwara S, Fukunaga M, Miki T, Yoshimura N (2013) Guidelines for the use of bone metabolic markers in the diagnosis and treatment of osteoporosis (2012 edition). J Bone Miner Metab 31:1\u201315","journal-title":"J Bone Miner Metab"},{"key":"829_CR9","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1056\/NEJMra067395","volume":"357","author":"E Canalis","year":"2007","unstructured":"Canalis E, Giustina A, Bilezikian JP (2007) Mechanisms of anabolic therapies for osteoporosis. N Engl J Med 357:905\u2013916","journal-title":"N Engl J Med"},{"key":"829_CR10","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1007\/s00774-015-0665-3","volume":"34","author":"S Nakatoh","year":"2016","unstructured":"Nakatoh S (2016) The importance of assessing the rate of bone turnover and the balance between bone formation and bone resorption during daily teriparatide administration for osteoporosis: a pilot study. J Bone Miner Metab 34:216\u2013224","journal-title":"J Bone Miner Metab"},{"key":"829_CR11","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/S0749-0690(02)00074-5","volume":"19","author":"MR Rubin","year":"2003","unstructured":"Rubin MR, Bilezikian JP (2003) The anabolic effects of parathyroid hormone therapy. Clin Geriatr Med 19:415\u2013432","journal-title":"Clin Geriatr Med"},{"key":"829_CR12","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.bone.2010.05.022","volume":"47","author":"A Miyauchi","year":"2010","unstructured":"Miyauchi A, Matsumoto T, Sugimoto T, Tsujimoto M, Warner MR, Nakamura T (2010) Effects of teriparatide on bone mineral density and bone turnover markers in Japanese subjects with osteoporosis at high risk of fracture in a 24-month clinical study: 12-month, randomized, placebo-controlled, double-blind and 12-month open-label phases. Bone 47:493\u2013502","journal-title":"Bone"},{"key":"829_CR13","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1111\/j.1365-2362.2009.02087.x","volume":"39","author":"C Bieglmayer","year":"2009","unstructured":"Bieglmayer C, Kudlacek S (2009) The bone marker plot: an innovative method to assess bone turnover in women. Eur J Clin Investig 39:230\u2013238","journal-title":"Eur J Clin Investig"},{"key":"829_CR14","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s00774-013-0447-8","volume":"31","author":"S Soen","year":"2013","unstructured":"Soen S, Fukunaga M, Sugimoto T, Sone T, Fujiwara S, Endo N, Gorai I, Shiraki M, Hagino H, Hosoi T, Ohta H, Yoneda T, Tomomitsu T (2013) Diagnostic criteria for primary osteoporosis: year 2012 revision. J Bone Miner Metab 31:247\u2013257","journal-title":"J Bone Miner Metab"},{"key":"829_CR15","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s00198-008-0748-2","volume":"20","author":"E Barrett-Connor","year":"2009","unstructured":"Barrett-Connor E, Weiss TW, McHorney CA, Miller PD, Siris ES (2009) Predictors of falls among postmenopausal women: result from the National Osteoporosis Risk Assessment (NORA). Osteoporos Int 20:715\u2013722","journal-title":"Osteoporos Int"},{"key":"829_CR16","first-page":"133","volume":"22","author":"S Nakatoh","year":"2014","unstructured":"Nakatoh S (2014) Utility of calculations bone turnover rates and bone formation\/resorption ratios in osteoporosis care (in Japanese). Osteoporos Jpn 22:133\u2013140","journal-title":"Osteoporos Jpn"},{"key":"829_CR17","doi-asserted-by":"publisher","first-page":"CR442","DOI":"10.12659\/MSM.881905","volume":"17","author":"A Panico","year":"2011","unstructured":"Panico A, Lupoli GA, Marciello F, Lupoli R, Cacciapuoti M, Martinelli A, Granieri L, Iacono D, Lupoli G (2011) Teriparatide vs. alendronate as a treatment for osteoporosis: changes in biochemical markers of bone turnover, BMD and quality of life. Med Sci Monit 17:CR442\u2013CR448","journal-title":"Med Sci Monit"},{"key":"829_CR18","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1002\/jbmr.2216","volume":"29","author":"C Muschitz","year":"2014","unstructured":"Muschitz C, Kocijan R, Fahrleitner-Pammer A, Pavo I, Haschka J, Schima W, Kapiotis S, Resch H (2014) Overlapping and continued alendronate or raloxifene administration in patients on teriparatide: effects on areal and volumetric bone mineral density\u2014the CONFORS Study. J Bone Miner Res 29:1777\u20131785","journal-title":"J Bone Miner Res"},{"key":"829_CR19","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s00774-015-0731-x","volume":"35","author":"K Ebina","year":"2017","unstructured":"Ebina K, Hashimoto J, Kashii M, Hirao M, Kaneshiro S, Noguchi T, Tsukamoto Y, Yoshikawa H (2017) The effects of switching daily teriparatide to oral bisphosphonates or denosumab in patients with primary osteoporosis. J Bone Miner Metab 35:91\u201398","journal-title":"J Bone Miner Metab"},{"key":"829_CR20","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0022-3565(24)38786-5","volume":"296","author":"JE Dunford","year":"2001","unstructured":"Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH, Rogers MJ (2001) Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 296:235\u2013242","journal-title":"J Pharmacol Exp Ther"},{"key":"829_CR21","volume-title":"Bisphosphonates in bone disease","author":"H Fleisch","year":"2000","unstructured":"Fleisch H (2000) Bisphosphonates in bone disease. Academic Press, San Diego"},{"key":"829_CR22","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1007\/s00198-008-0816-7","volume":"20","author":"T Matsumoto","year":"2009","unstructured":"Matsumoto T, Hagino H, Shiraki M, Fukunaga M, Nakano T, Takaoka K, Morii H, Ohashi Y, Nakamura T (2009) Effect of daily oral minodronate on vertebral fractures in Japanese postmenopausal women with established osteoporosis: a randomized placebo-controlled double-blind study. Osteoporos Int 20:1429\u20131437","journal-title":"Osteoporos Int"},{"key":"829_CR23","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1007\/s00198-003-1424-1","volume":"14","author":"H Morii","year":"2003","unstructured":"Morii H, Ohashi Y, Taketani Y, Fukunaga M, Nakamura T, Itabashi A, Sarkar S, Harper K (2003) Effect of raloxifene on bone mineral density and biochemical markers of bone turnover in Japanese postmenopausal women with osteoporosis: results from a randomized placebo-controlled trial. Osteoporos Int 14:793\u2013800","journal-title":"Osteoporos Int"},{"key":"829_CR24","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.bone.2011.07.011","volume":"49","author":"T Matsumoto","year":"2011","unstructured":"Matsumoto T, Ito M, Hayashi Y, Hirota T, Tanigawara Y, Sone T, Fukunaga M, Shiraki M, Nakamura T (2011) A new active vitamin D3 analog, eldecalcitol, prevents the risk of osteoporotic fractures\u2014a randomized, active comparator, double-blind study. Bone 49:605\u2013612","journal-title":"Bone"},{"key":"829_CR25","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s00774-011-0332-2","volume":"30","author":"H Hagino","year":"2012","unstructured":"Hagino H, Shiraki M, Fukunaga M, Nakano T, Takaoka K, Ohashi Y, Nakamura T, Matsumoto T (2012) Three years of treatment with minodronate in patients with postmenopausal osteoporosis. J Bone Miner Metab 30:439\u2013446","journal-title":"J Bone Miner Metab"},{"key":"829_CR26","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1359\/JBMR.041114","volume":"20","author":"BL Riggs","year":"2005","unstructured":"Riggs BL, Parfitt AM (2005) Drugs used to treat osteoporosis: the critical need for a uniform nomenclature based on their action on bone remodeling. J Bone Miner Res 20:177\u2013184","journal-title":"J Bone Miner Res"},{"key":"829_CR27","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1002\/jbmr.1496","volume":"27","author":"A D\u00edez-P\u00e9rez","year":"2012","unstructured":"D\u00edez-P\u00e9rez A, Olmos JM, Nogu\u00e9s X, Sosa M, D\u00edaz-Curiel M, P\u00e9rez-Castrill\u00f3n JL, P\u00e9rez-Cano R, Mu\u00f1oz-Torres M, Torrijos A, Jodar E, Del Rio L, Caeiro-Rey JR, Farrerons J, Vila J, Arnaud C, Gonz\u00e1lez-Mac\u00edas J (2012) Risk factors for prediction of inadequate response to antiresorptives. J Bone Miner Res 27:817\u2013824","journal-title":"J Bone Miner Res"},{"key":"829_CR28","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.jsbmb.2006.12.088","volume":"103","author":"T Matsumoto","year":"2007","unstructured":"Matsumoto T, Kubodera N (2007) ED-71, a new active vitamin D3, increases bone mineral density regardless of serum 25(OH)D levels in osteoporotic subjects. J Steroid Biochem Mol Biol 103:584\u2013586","journal-title":"J Steroid Biochem Mol Biol"}],"container-title":["Journal of Bone and Mineral Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00774-017-0829-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-017-0829-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-017-0829-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T20:22:15Z","timestamp":1750105335000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00774-017-0829-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,14]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["829"],"URL":"https:\/\/doi.org\/10.1007\/s00774-017-0829-4","relation":{},"ISSN":["0914-8779","1435-5604"],"issn-type":[{"type":"print","value":"0914-8779"},{"type":"electronic","value":"1435-5604"}],"subject":[],"published":{"date-parts":[[2017,3,14]]},"assertion":[{"value":"16 September 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"This study was planned as an investigator-initiated study, and necessary costs were supported by a research grant from Astellas Pharma.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}